HPV阳性头颈癌从手术到放疗的时间与多模式治疗结局的关联:多机构队列经验
该多机构队列纳入96例接受多模式治疗的非转移性高危HPV阳性口咽鳞状细胞癌患者,评估手术至放疗开始时间(TSRT)超过6周与无复发生存的关系。中位随访62个月,TSRT超过6周与较差结局无显著关联;作者认为较长的TSRT可能有助于手术毒性恢复而不影响肿瘤学结局。
要点
- 96例高危HPV阳性口咽鳞癌患者中,TSRT超过6周与治疗失败无显著关联。
- 中位TSRT为38天,中位随访62个月,10例出现治疗失败。
- 延长TSRT可能允许手术毒性恢复而不影响肿瘤学结局,但需未来研究验证TSRT目标。
核心结论
- 在HPV阳性口咽鳞癌术后管理中,TSRT超过6周与较差结局无显著关联。
- 较长的TSRT可能有助于按需从手术毒性中恢复,而不影响肿瘤学结局。
- 这些癌症的TSRT目标应在未来研究中探讨。
研究设计与样本
- 多机构队列研究,纳入2个机构的非转移性高危HPV阳性口咽鳞状细胞癌患者,均接受多模式治疗。
- 共纳入96例患者,其中69例接受经口机器人手术,27例接受开放手术。
- 延长TSRT定义为超过6周,评估其与无复发生存(RFS)的关联,并评估放疗治疗时间(RTT)、总治疗包时间(TTPT)、降剂量放疗(剂量≤56 Gy)、同步化疗、吸烟史和治疗机构作为可能的混杂因素。
主要发现
- 中位随访时间为62个月(范围4-123个月),中位术后放疗剂量为60 Gy(范围50-70.8 Gy)。
- 中位TSRT为38天(范围11-208天),中位RTT为43天(范围26-56天),中位TTPT为81天(范围40-255天)。
- 10例患者出现治疗失败,中位失败时间为8个月(范围4-64个月)。
- 未延长TSRT组发生2例局部区域失败和4例远处失败,延长TSRT组记录2例局部区域失败和2例远处失败。
- 延长TTPT、降剂量放疗、化疗、吸烟史和治疗机构与治疗失败无关联;RTT因延长RTT组无事件且无法计算可靠风险比而被剔除分析。
关键数值与推荐
- NCCN推荐手术至放疗开始时间(TSRT)保持在6周以内,以避免可能影响患者结局。
- 延长TSRT定义为超过6周。
- 降剂量放疗定义为剂量≤56 Gy。
临床怎么用
- 作者认为,对于HPV阳性口咽鳞癌术后患者,较长的TSRT可能有助于按需从手术毒性中恢复,而不影响肿瘤学结局。
- 原文未据此给出推荐。
局限性
- RTT因延长RTT组无事件且无法计算可靠风险比而被剔除分析。
- 这些癌症的TSRT目标应在未来研究中探讨。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Oropharyngeal squamous cell cancers (OPSCCs) are traditionally managed with surgery and, if indicated, adjuvant radiation therapy (RT) with or without chemotherapy. NCCN recommends keeping the time from surgery to the start of RT (TSRT) within 6 weeks to avoid possibly compromising patient outcomes. HPV+ OPSCCs behave more favorably than HPV- OPSCCs. We hypothesized that TSRT beyond 6 weeks may not portend poorer outcomes for the former. METHODS: We identified nonmetastatic, high-risk HPV+ OPSCCs treated with multimodal therapy at 2 institutions. Prolonged TSRT was defined as >6 weeks and was evaluated for association with recurrence-free survival (RFS). Radiation treatment time (RTT; time from the first to the last day of RT), total treatment package time (TTPT; time from surgery to the end of adjuvant treatments), de-escalated RT (dose ≤56 Gy), concurrent chemotherapy, smoking history, and treatment institution were evaluated as possible confounders. RESULTS: In total, 96 patients were included. The median follow-up time was 62 months (4-123 months); 69 patients underwent transoral robotic surgeries, and 27 received open surgeries. The median postoperative RT dose was 60 Gy (50-70.8 Gy). The median TSRT, RTT, and TTPT were 38 days (11-208), 43 days (26-56 days), and 81 days (40-255 days), respectively. Ten patients failed treatment at a median of 8 months (4-64 months). Two locoregional and 4 distant failures occurred in the group without prolonged TSRT, whereas 2 locoregional and 2 distant failures were recorded in the prolonged TSRT group. Prolonged TTPT, de-escalated RT, chemotherapy, smoking history, and treatment institution were not associated with treatment failure. RTT was dropped from our analyses as no events appeared in the prolonged RTT group, and no reliable hazard ratio could be computed. CONCLUSIONS: TSRT > 6 weeks was not significantly associated with inferior outcomes in the postoperative management of HPV+ OPSCCs. Longer TSRT may facilitate better recovery from surgical toxicity, as needed, without compromising oncologic outcomes. The TSRT goal for these cancers should be investigated in future studies.
引用
- Niazi M, Miller R, Kolb R, et al. Association Between Time From Surgery to Radiation Therapy and Multimodality Treatment Outcomes in HPV+ Head and Neck Cancer: A Multi-Institutional Cohort Experience. Adv Radiat Oncol. 2024. PMID: 38993193. doi:10.1016/j.adro.2024.101515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。